What is the role of gemcitabine in bladder carcinoma in situ treatment?

Updated: Oct 24, 2019
  • Author: Stanley A Brosman, MD; Chief Editor: Bradley Fields Schwartz, DO, FACS  more...
  • Print


Gemcitabine is the most recent addition to the list of effective intravesical agents. [8] This chemotherapy drug is administered according to the same protocol as BCG (ie, 6 weekly treatments followed by maintenance for 1 y). This agent has caused very few side effects.

Gemcitabine is a prodrug that requires activation by intracellular phosphorylation. It has shown selective killing in human transitional cell carcinoma (TCC) cell lines and does not affect normal fibroblast cell lines. Serial administration of weekly doses of 1500-2000 mg in 50 mL of saline has shown complete responses in 50% of patients with CIS.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!